Grandfield & Dodd’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.48M Buy
27,109
+670
+3% +$32.6K 0.08% 96
2026
Q1
$1.13M Sell
26,439
-630
-2% -$27.1K 0.06% 105
2025
Q4
$1.19M Buy
27,069
+68
+0.3% +$2.81K 0.07% 106
2025
Q3
$1.12M Buy
27,001
+600
+2% +$24.1K 0.06% 107
2025
Q2
$1.16M Buy
26,401
+70
+0.3% +$2.8K 0.07% 104
2025
Q1
$972K Buy
26,331
+4,465
+20% +$159K 0.06% 108
2024
Q4
$728K Buy
21,866
+9,846
+82% +$319K 0.04% 121
2024
Q3
$312K Buy
+12,020
New +$299K 0.02% 172

Other funds holding EXEL

Grandfield & Dodd's EXEL Position: Q2 2026 in Review

Grandfield & Dodd increased its Exelixis (EXEL) stake by 2.5% in Q2 2026, buying an estimated $32.6K and bringing the position to 27,109 shares worth $1.48M. The position accounts for 0.08% of the portfolio, ranked #96.

Grandfield & Dodd first reported a position in EXEL in Q3 2024 and has held it in 8 quarters since. 759 funds tracked by Wall St. Rank hold EXEL as of Q2 2026.

  • Grandfield & Dodd held 27,109 shares of Exelixis worth $1.48M as of Q2 2026.
  • Grandfield & Dodd bought 670 Exelixis shares in Q2 2026, an estimated $32.6K.
  • Exelixis made up 0.08% of Grandfield & Dodd's portfolio in Q2 2026, its #96 holding.
  • Grandfield & Dodd first reported a position in Exelixis in Q3 2024 and has held it in 8 quarters since.
  • 759 funds tracked by Wall St. Rank held Exelixis as of Q2 2026.

Based on Grandfield & Dodd's 13F filing for Q2 2026, filed 7 Aug 2026.